臨床研究等提出・公開システム

Cross sectional study to investigate the difference in needs between patients and health care providers for systemic therapy of renal cell carcinoma

Cross sectional study to investigate the difference in needs between patients and health care providers for systemic therapy of renal cell carcinoma

83

Patients: 63.9% were male and mean age was 44.2. Physicians: mean year of experience in RCC treatment was 15.8 and 62.4% was urologist. Nurses: Mean year of experience as nurse was 12.8. Pharmacists: Mean year of experience as pharmacist was 9.0.

101 patients, 183 physicians, 220 nurses and 221 pharmacists participated in the survey. Due to some contradictory answers, 83 patients, 165 physicians, 218 nurses and 218 pharmacists were analyzed.

N/A

Among the 11 attributes of expectations for systemic therapy, the most important attribute for mRCC patients was chance of eliminating all evidence of disease. For physicians, the most important attribute of expectations regarding systemic therapy was longer survival.

This study demonstrated a gap between patients with mRCC and physicians in their expectations and concerns for systemic therapy. Japanese patients with mRCC suffer from a number of adverse events, some of which are not shared with physicians. This study highlights the importance of communicating well with patients in clinical practice to achieve patient-centricity in systemic treatment for mRCC.

Oct. 22, 2022

Oct. 22, 2022

No

https://jrct.mhlw.go.jp/latest-detail/jRCT1040220016

Hiromi Kitano

Eisai Co., Ltd.

4-6-10, Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

h-kitano@hhc.eisai.co.jp

Yoshihide Mitsuda

Eisai Co., Ltd.

4-6-10, Koishikawa, Bunkyo-ku, Tokyo 112-8088, Japan

+81-70-4560-7293

y2-mitsuda@hhc.eisai.co.jp

Complete

May. 03, 2022

Observational

<Patients>
- Agreed web questionnaire survey.
- 20 year and older.
- Live in Japan.
- Received or ongoing molecular targeted therapy or immune checkpoint inhibitor (including combination therapy) for renal cell carcinoma.
<Health care providers>
- Agreed web questionnaire survey.
- Doctors, nurses, or pharmacists who are engaged in systemic therapy of renal cell carcinoma.

<Patients>
- Have families engaged in pharmatheutical/survey/marketing company or health care.
- Have double cancer.
<Health care providers>
- Doctors, nurses, or pharmacists who are not engaged in systemic therapy of renal cell carcinoma.

Both

Renal cell carcinoma

D046650

Difference in preferences of systemic therapy between patients and doctors.

- Difference in preferences of systemic therapy between patients and nurses or pharmacists.
- Health care providers who have the most similar preferences of systemic therapy to patients.
- The most painful adverse events for patients.
- Adverse events which patients are reluctant to tell health care providers.
- Difference in recognitions of adverse events between patients and health care providers.
- Adverse events which need intervention of nurses or pharmacists.
- The most difficult adverse events to manage for health care providers.
- Difference in recognitions of adverse events which need intervention of nurses or pharmacists between doctors, nurses, and pharmacists.
- Recognition of health care providers for employment status of patients.
- Recognition of health care providers for cost of systemic therapy.

+81-527456881

April. 27, 2022

none